Pages
Blogroll
- Blood Pressure Risk Factors
- Electric mobility scooters
- Hair Growth Product Reviews
- Hoveround Wheelchairs
- Medical Scales
- Mortgage modification trial payments
- NBA Basketball Betting
- Nursing career
- Pancreas Cancer
- Prevent Cancer
- Prostate Cancer Treatment Side Effects
- Type 2 Diabetes Mellitus
Categories
- Cancer Risk
- Cells and Organs
- General Information
- Prostate Help Organizations
- UK Prostate Cancer
- Uncategorized
Archives
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
Meta
ZD4054 is a potential anti-cancer agent now in a clinical trials around the world for men with metastatic hormone refractory prostate cancer (HRPC) and for men with non-metastatic hormone refractory prostate cancer.
The trials are run by pharmaceutical company AstraZeneca, which makes ZD4054. These two distinct trials differ significantly in the level of therapy offered to [...] (Source: psa-rising.com/blog)
Original post by psa-rising.com/blog and software by Elliott Back
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.